AI assistant
Sending…
Celldex Therapeutics, Inc. — Director's Dealing 2018
Jun 18, 2018
31801_dirs_2018-06-18_e528247d-88d3-4bc5-bbea-ec5d44186f00.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Celldex Therapeutics, Inc. (CLDX)
CIK: 0000744218
Period of Report: 2018-06-15
Reporting Person: KELER TIBOR (Executive VP & CSO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-06-15 | Common Stock, par value $0.001 per share | P | 16500 | $.5929 | Acquired | 35368 | Direct |
More from Celldex Therapeutics, Inc.
Interim / Quarterly Report
2026
May 7
Regulatory Filings
2026
May 7
Major Shareholding Notification
2026
May 6
Major Shareholding Notification
2026
Apr 29
Annual Report
2026
Apr 29
Proxy Solicitation & Information Statement
2026
Apr 29
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 2
Regulatory Filings
2026
Apr 1
Major Shareholding Notification
2026
Mar 26